- Home
- News
- Articles+
- Aerospace
- Agriculture
- Alternate Dispute Resolution
- Banking and Finance
- Bankruptcy
- Book Review
- Bribery & Corruption
- Commercial Litigation
- Competition Law
- Conference Reports
- Consumer Products
- Contract
- Corporate Governance
- Corporate Law
- Covid-19
- Cryptocurrency
- Cybersecurity
- Data Protection
- Defence
- Digital Economy
- E-commerce
- Employment Law
- Energy and Natural Resources
- Entertainment and Sports Law
- Environmental Law
- FDI
- Food and Beverage
- Health Care
- IBC Diaries
- Insurance Law
- Intellectual Property
- International Law
- Know the Law
- Labour Laws
- Litigation
- Litigation Funding
- Manufacturing
- Mergers & Acquisitions
- NFTs
- Privacy
- Private Equity
- Project Finance
- Real Estate
- Risk and Compliance
- Technology Media and Telecom
- Tributes
- Zoom In
- Take On Board
- In Focus
- Law & Policy and Regulation
- IP & Tech Era
- Viewpoint
- Arbitration & Mediation
- Tax
- Student Corner
- AI
- ESG
- Gaming
- Inclusion & Diversity
- Law Firms
- In-House
- Rankings
- E-Magazine
- Legal Era TV
- Events
- News
- Articles
- Aerospace
- Agriculture
- Alternate Dispute Resolution
- Banking and Finance
- Bankruptcy
- Book Review
- Bribery & Corruption
- Commercial Litigation
- Competition Law
- Conference Reports
- Consumer Products
- Contract
- Corporate Governance
- Corporate Law
- Covid-19
- Cryptocurrency
- Cybersecurity
- Data Protection
- Defence
- Digital Economy
- E-commerce
- Employment Law
- Energy and Natural Resources
- Entertainment and Sports Law
- Environmental Law
- FDI
- Food and Beverage
- Health Care
- IBC Diaries
- Insurance Law
- Intellectual Property
- International Law
- Know the Law
- Labour Laws
- Litigation
- Litigation Funding
- Manufacturing
- Mergers & Acquisitions
- NFTs
- Privacy
- Private Equity
- Project Finance
- Real Estate
- Risk and Compliance
- Technology Media and Telecom
- Tributes
- Zoom In
- Take On Board
- In Focus
- Law & Policy and Regulation
- IP & Tech Era
- Viewpoint
- Arbitration & Mediation
- Tax
- Student Corner
- AI
- ESG
- Gaming
- Inclusion & Diversity
- Law Firms
- In-House
- Rankings
- E-Magazine
- Legal Era TV
- Events
S&R Associates represented Ennov on acquisition of Calyx’s ‘Enterprise Technology’
S&R Associates represented Ennov on acquisition of Calyx’s ‘Enterprise Technology’
While enlarging the global footprint, it addresses the evolving needs of the trade with unparalleled flexibility and accuracy
S&R Associates is representing Ennov, a software solutions provider for the life sciences industry, on Indian legal aspects of its proposed acquisition of the ‘Enterprise Technology’ division of Calyx, a clinical research and regulatory solutions provider.
The acquisition significantly expands Ennov’s portfolio by integrating the advanced eClinical and eRegulatory solutions from Calyx’s ‘Enterprise Technology’ division, previously part of Parexel.
This division is known for its flagship regulatory solution suite, popular in the market as Liquent InSight, which provides integrated eCTD publishing and regulatory information management capabilities. The solution represents a key component of Calyx’s offerings and is highly regarded for its impact and innovation in streamlining drug development processes.
Ennov’s established presence in Europe and Southeast Asia, combined with Calyx’s strong foothold in the US and India, creates a comprehensive and powerful global network.
Through innovative eClinical Solutions and services, Calyx turns the uncertain into the reliable, helping bring new medical treatments to market faster. With deep expertise in clinical development and more than 25 years of supporting trial sponsors and clinical research organizations, Calyx harnesses that intelligence and activates its potential to solve complex problems, deliver fast insights, and get new drugs to market regularly.
Ennov provides a comprehensive software platform to manage the most demanding processes of life sciences organizations in a compliant and efficient way. With over 20 years of experience, its cloud-based solutions cover regulatory affairs, pharmacovigilance, quality, clinical, and document management. Dedicated to innovation and excellence, Ennov’s solutions are used by over 500 companies and 150,000 users worldwide. It helps in bringing their products to market faster while maintaining compliance with regulatory requirements.
The S&R team is led by partners Rajat Sethi and Lakshmi Pradeep. It includes associates Rishabh Uppal and Pradhumna Mohan Dixit (corporate matters); Simran Dhir (head of competition practice); counsel Akshat Kulshrestha and associate Anuja Agrawal (competition law); partner Sumit Bansal and associates Shivani Chhabra and Taranjeet Singh (tax matters).